Analysts are looking for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report EPS of $0.55 for the quarter on a consensus basis. This estimate is provided by Zacks Research including the covering analysts polled. The EPS estimate may vary from other data providers that provide consensus numbers. For the period ending on 2016-06-30, the company reported EPS of $0.17 for the quarter. The actual reported number was $-0.05 away from the consensus estimate. This created a surprise factor of -22.73%.
In taking a look at where analysts believe Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is headed, the covering brokerages have a one year target price of $139.333 on the shares. This is based on the 6 analysts polled by Zacks Research. The analyst with the most aggressive viewpoint sees the stock heading towards $160 within the next 12 months while the most bearish sees the shares going to $105 in that same timeframe. The most recent analyst revision occurred on 2016-09-28. Depending on the brokerage firm, analysts on the sell-side use alternate terminology to describe their Buy/Sell recommendations.
Retail investors not familiar with a particular firms reports could find the recommendations difficult to understand. As a result, Zacks offers an analyst brokerage rating (ABR) which simplifies the recommendations into a 1 to 5 sliding scale where one represents a Strong Buy and 5 indicates a Strong Sell. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) currently has an ABR 1.33. This is the average recommendation based on the 6 analysts polled.
Please note that the data derived in this report is from Zacks Research. This is not a recommendation to Buy or Sell shares of Ligand Pharmaceuticals Incorporated. The author of this article does not hold any position in the company. Investors should conduct their own thorough research before buying or selling equities.